This has been a blockbuster year for federal regulators investigating bribery in the pharmaceutical industry.
Three of the world’s biggest drug companies, along with two smaller companies, agreed to pay a collective $63 million this year to settle allegations that they violated the US Foreign Corrupt Practices Act by bribing doctors and government officials to promote their medicines overseas.
About the Author Reprints
